We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Respiratory Disease and Thoracic Surgery



October 2018

Cysteamine bitartrate for cystic fibrosis exacerbations

Cysteamine bitartrate as an oral formulation is a novel treatment of exacerbations of CF-associated lung disease, with a unique multi-action: breaking down of the excessive mucus produced by the lining of the airways, killing of the bacteria responsible for the recurrent respiratory infections, and disrupting the biofilms in which they colonise. Cysteamine bitartrate also potentiates the activity of standard of care antibiotics used in CF patients, and is potentially antibiotic-sparing as an adjunct treatment alongside standard of care therapy. If licensed, cysteamine bitartrate will offer an additional treatment option for adult patients with CF exacerbations.


June 2018

Lumacaftor and Ivacaftor (Orkambi) for Cystic Fibrosis Homozygous for the F508del CFTR mutation in patients aged 2-5 years old

Cystic fibrosis is an inherited disease that has severe effects on the lungs and the digestive system. It affects the cells that produce mucus and digestive juices. In cystic fibrosis, the secretions become thick and cause blockage within the tissues and organs (mostly within the lungs). Build-up of thick and sticky secretions in the lungs …


May 2018

Lumacaftor and Ivacaftor (Orkambi) for Cystic Fibrosis Homozygous for the F508del Mutation in Patients Aged 6‐11 Years

Lumacaftor and ivacaftor (Orkambi) is a medicine used to treat cystic fibrosis in patients aged 6 years and above who have a genetic mutation called the F508del mutation. This mutation affects the gene for a protein called cystic fibrosis transmembrane conductance regulator (CFTR) which is involved in regulating the production of mucus and digestive juices. Orkambi is used in patients who have inherited the mutation from both parents and therefore have the mutation in both copies of the CFTR gene. Orkambi is taken orally as tablets twice a day. It offers a new treatment option for patients with cystic fibrosis with the advantage of targeting the actual disease process rather than just the symptoms.


January 2018

Nintedanib for Systemic Sclerosis Associated Interstitial Lung Disease

Nintedanib (OFEV®) is a medicine that is being developed for the treatment of Systemic Sclerosis associated interstitial lung disease (SSc-ILD). It acts by targeting the specific mechanisms by which scarring of the lungs occur, reducing progression of the disease. It is given by mouth as capsules. Nintedanib (as OFEV) is already available in the EU for the treatment of idiopathic pulmonary fibrosis (IPF). Because SSc-ILD and IPF share similarities in how the underlying lung scarring, or fibrosis, forms in people with the disease, the development of nintedanib for the treatment of SSc-ILD may address unmet needs. If licensed, nintedanib may offer an additional treatment option (the first licensed) for patients with SSc-ILD.


November 2017

Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)

Benralizumab is a new drug being developed for the treatment of chronic obstructive pulmonary
disease. It is administered by injection under the skin and acts by targeting specific proteins that
causes the airway to narrow. If benralizumab is licensed for use in the UK, it could be a new treatment
option for patients with chronic obstructive pulmonary disease that may improve quality of life and
reduce the number of exacerbations.


August 2017

Tralokinumab for severe, uncontrolled asthma

Asthma is a long-term condition that affects the lungs and breathing. People with asthma have symptoms such as coughing, wheezing, chest tightness and breathlessness. Some people have symptoms despite trying various treatments or may suffer from more sudden ‘asthma attacks’. Severe asthma attacks can lead to hospitalisation, and on rare occasions can be life threatening. …


March 2017

Nyxoah Genio™ System for obstructive sleep apnoea

The Nyxoah Genio™ system is a device to treat people with obstructive sleep apnoea (OSA) who are not suitable for continuous positive airway pressure (CPAP) therapy. OSA is a common sleep disorder where the walls of the throat relax and narrow during sleep, interrupting normal breathing. The Nyxoah Genio™ system consists of a device which …


November 2016

Ivacaftor with tezacaftor for cystic fibrosis with a homozygous or heterozygous F508del CFTR mutation

Cystic fibrosis is a long-term condition which affects the lungs and digestive system. The lungs can become clogged with thick, sticky mucus, which can cause problems with breathing from a young age. Over many years,  the lungs become increasingly damaged and may eventually stop working properly. The damage gets worse over time and many people …


September 2016

Molgramostim inhalation for autoimmune pulmonary alveolar proteinosis

Molgramostim inhalation is a new drug to treat autoimmune pulmonary alveolar proteinosis (PAP). Autoimmune PAP is a rare lung disease that causes a build-up of protein material in the air sacs of the lungs, making it difficult to breath. Molgramostim inhalation is breathed in and works by altering the body’s immune response, helping to prevent …


August 2016

Mepolizumab (Nucala) for chronic obstructive pulmonary disease with eosinophilic bronchitis – add on therapy

Chronic obstructive pulmonary disease (sometimes called chronic bronchitis or emphysema) is a lung disease that causes difficulties in breathing, mostly due to narrowing of the airways. The main cause of chronic obstructive pulmonary disease is smoking. Symptoms of this disease include increased difficulty breathing when active, persistent cough, and frequent chest infections. Patients with chronic …

Get Alerts